Providing additional opportunities for the monetisation of life sciences IP, the drug royalty market continued to develop in 2020, producing a slew of new deals with creative and flexible structures
Providing additional opportunities for the monetisation of life sciences IP, the drug royalty market continued to develop in 2020, producing a slew of new deals with creative and flexible structures